HILLSIDE, N.J., Dec. 21 /PRNewswire-FirstCall/ -- Integrated BioPharma, Inc. announced today the appointment of General James T. Hill, USA (Ret.) as a director of InB: Biotechnologies, Inc., its wholly-owned subsidiary.
At the time of his retirement from active duty in November of 2004, General Hill was the Commander of the United States Southern Command, a 4-Star command, reporting directly to the President and Secretary of Defense. As such he led all U.S. military forces and operations in Central America, South America and the Caribbean, worked directly with U.S. Ambassadors, foreign heads of state, key Washington decision-makers, foreign senior military and civilian leaders, developing and executing United States policy. His responsibilities included management, development and execution of plans and policy within the organization including programming, communications, manpower, operations, logistics and intelligence.
InB: Biotechnologies, Inc., the biotechnology arm of InB, has been engaged in the development of a novel, proprietary, plant-based platform for the production of vaccines, certain drugs and nutraceuticals. Pursuant to a cooperative research and development agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC), InB: Biotechnologies is about to commence an IND human clinical trial of an oral anthrax vaccine using InB’s plant-based platform, in connection with the Bio-Defense Program (under the Biological Defense Research Directorate) for the United States.
In addition, InB: Biotechnologies and its contract research partner, Fraunhofer USA, are about to commence animal trials of an avian flu vaccine, based upon InB: Biotechnologies’ plant-based platform, in order to validate and establish this new platform for the production of a vaccine against influenza that would materially decrease the time lag between the identification of the current strain and the availability of sufficient quantities of an accurately targeted vaccine to immunize large populations parenterally and intranasally, as a defense against pandemic disease.
“We are very pleased to have General Hill join our efforts to provide solutions against chemical and biological bioterrorism agents and against pandemic influenza risks,” said Gerald Kay, CEO of InB. “We believe his extensive management and governmental relations knowledge and experience will enhance our abilities to obtain the necessary cooperation and assistance from both governmental entities and the private sector as we proceed with further validation of what we believe is important new technology in the vaccine area.”
About Integrated BioPharma, Inc. (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company’s biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company’s financial results can be found in the company’s Reports filed with the Securities and Exchange Commission.
Contact: Dina Masi, CFO Integrated BioPharma, Inc. 888-319-6962 d.masi@ibiopharma.com
Integrated BioPharma, Inc.
CONTACT: Dina Masi, CFO of Integrated BioPharma, Inc., +1-888-319-6962,d.masi@ibiopharma.com
Web site: http://www.ibiopharma.com/